Risk analysis of dextromethorphan abuse

doi:10.19803/j.1672-8629.20220376

Abstract

Abstract: Objective To explore the risk of dextromethorphan abuse and provide basis for clinical rational drug use. Methods The occurrence and characteristics of dextromethorphan abuse cases in literature reports in CNKI and Wanfang from 1999 to 2020 and related drug safety databases were analyzed. The causes of dextromethorphan abuse and the measures taken by the regulatory authorities were discussed. Results and Conclusion Dextromethorphan preparations are at risk of abuse for non-medical purposes, including in the adolescent. The availability of over-the-counter drugs and improper self-medication can increase the risk of abuse.

Key words: dextromethorphan, drug abuse, adverse drug reaction, risk analysis

CLC Number:

R969.3
R974

WANG Dan, WU Chen, REN Jingtian. Risk analysis of dextromethorphan abuse[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1097-1099.

References

[1] NMPA.Notice on publishing the first batch of national OTC drugs catalogue (western medicine, chinese patent medicine) [EB/OL].(1999-06-11)[2022-06-30]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/19990611010101639.html.
[2] DING Y, XIA L, DUAN L, et al.Clinical analysis of 13 patients with dextromethorphon dependence[J]. Chinese Journal of Drug Abuse Prevention and Treatment, 2021, 27(2): 155-158.
[3] NMPA. Announcement of the NMPA on the conversion of dextromethorphan hydrobromide oral monoprescription into prescription drugs (No. 151, 2021) [EB/OL]. (2021-12-16)[2022-06-23]. https://www.nmpa.gov.cn/yaopin/ypggtg/20211227162159192.html.
[4] QUAN DM.A case of forensic identification of mental disorders caused by abuse of dextromethorphan[C]. Proceedings of the 10th National Judicial Psychiatry Academic Conference, 2007: 355-357.
[5] HE RH, WANG XL, CHEN HL, et al.A case of dextromethorphan abuse[J]. Chinese Journal of Drug Dependence, 2008, 17(5): 399.
[6] DUAN L.Analysis of clinical characteristics of 27 cases of dextromethorphan abuse[C]. Proceedings of the 2015 National Symposium on drug abuse prevention and control and the 9th Symposium on drug abuse prevention and control in the mainland, Hong Kong and Macao, 2015: 340-344.
[7] CHEN YL, XU W.Juvenile poisoning caused by drug abuse of dextromethorphan hydrobromide[J]. Chinese Pediatric Emergency Medicine, 2017, 24(5): 388-390.
[8] XI W, LI SG.A case of severe drug dependence caused by dextromethorphan hydrobromide tablets[J]. Chinese Journal of Drug Abuse Prevention and Treatment, 2019, 25(1): 52.
[9] XU FQ, XU J, LIU ZS.Two cases of dependence caused by abuse of dextromethorphan hydrobromide[J]. Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine(Electronic), 2019, 7(12): 188.
[10] ZHANG XB.2 cases of drug addiction caused by repeated oral administration of dextromethorphan[J]. Chinese Journal of Drug Abuse Prevention and Treatment, 2020, 26(1): 34-35,42.
[11] XU J, SUN P, LIU Y, et al.A case of adult dextromethorphan hydrobromide drug abuse and literature review[J]. Chinese Journal of Drug Dependence, 2020, 29(1): 78-79.
[12] SCHWARTZ RH.Adolescent abuse of dextromethorphan[J]. Clin Pediatr (Phila), 2005, 44(7): 565-568.
[13] CAO J.Abuse of dextromethorphan is potentially dangerous and may cause death[J]. Foreign Pharmaceutical News, 2005(12): 33-35.
[14] Drug Enforcement Administration.Dextromethorphan (Street Names: DXM, CCC, Triple C, Skittles, Robo, Poor Man's PCP)[EB/OL]. [2022-06-30].https://www.deadiversion.usdoj.gov/drug_chem_info/dextro_m.pdf.
[15] FDA. Memorandum from September 14, 2010, DSaRM Advisory Committee Meeting[EB/OL]. (2010-08-23)[2022-06-23].https://www.fda.gov/advisory-committees/human-drug-advisory-committees/drug-safety-and-risk-management-advisory-committee.
[16] IRWIN RS.Diagnosis and management of cough: ACCP evidence-based clinical practice guidelines[J]. Chest, 2006, 129(1): 1S-292S.
[17] LI DK, JIN YY, TANG G, et al.Martindale—The Complete Drug Reference[M]. Beijing: Chemical Industry Press, 2008: 1225
[18] SFDA. Notice on printing and distributing 6 technical documents about the guiding principles for the evaluation of the conversion of prescription drugs to OTC drugs (for Trial Implementation) - Annex 6[EB/OL]. (2012-11-14)[2022-06-23]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20121114120001923.html.